well-described, likely due to legal and ethical restrictions in performing randomized controlled trials establishing the efficacy of a new AED.
In adults with newly diagnosed epilepsy, approximately one half of patients become seizure free with the first prescribed AED. [8] [9] [10] In limited studies that addressed this issue in children, the effectiveness rates have been reported between 60 and 80%. [11] [12] [13] [14] The main reasons for treatment failures are lack of efficacy and intolerability due to adverse effects. 13 While some studies have demonstrated that the most commonly used AEDs including valproate, carbamazepine and phenobarbital were found to be equivalent in terms of seizure control and adverse effects, 14, 15 others reported significant differences between the drug groups. 3, 16 Moreover, data on effectiveness of new AEDs including oxcarbazepine and levetiracetam have been more limited. [17] [18] [19] In the present study, we aimed to investigate the efficacy and tolerability of old and new AEDs in children with newly diagnosed idiopathic epilepsy when used as a first-line treatment.
Materials and methods
Hospital charts of children (ranging from 1 month to 18 years), who admitted to pediatric neurology out-patient clinic at Dr Behçet Uz Children's Hospital between July 01, 2011 and May 01, 2013, were retrospectively reviewed. Children with newly onset idiopathic epilepsy, who were initiated with phenobarbital, valproate, carbamazepine, oxcarbazepine, or levetiracetam monotherapy, were included if data were available regarding a follow-up period of 12 months. Patients were excluded from the study if they were diagnosed with symptomatic or cryptogenic epilepsy, those previously received antiepileptic drug therapy or if they had less than one seizure per year prior to treatment. Patients with evidence of persistent nonadherence to medication therapy, those using more than one AEDs, those with documented pseudoseizures, and those with concurrent neurologic or other chronic disorders were excluded. Patients who were diagnosed with drug resistant epilepsy during a twelve month follow-up period after the first drug failure were also excluded in order to eliminate the impact of that some of the AEDs might have been chosen for patients with more severe epilepsy, which, in turn, might have them labeled incorrectly as less effective. Newly onset epilepsy was defined as two or more unprovoked seizures. Drug resistant epilepsy was defined as failure of adequate trials of two tolerated, appropriately chosen and used AED schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. 20 Institutional Ethical Commitee approved the study.
Each child was assessed with a standardized work-up and follow-up, and all the demographic, clinical, laboratory, electroencephalographic and radiologic results were recorded into a standardized form. Following a thorough history, a detailed physical and neurologic examination was performed, and electroencephalography and magnetic resonance imaging (MRI) of the brain were obtained. Antiepileptic drugs were selected by the doctors on the basis of their experience and largely according to the International League Against Epilepsy (ILAE) recommendations. 21 Initial doses of AEDs were titrated to the maximal limit of tolerability in patients still reporting seizures. Detailed information including age, diagnosis, sex, birth history, past and family history of the patients, type of seizures, etiology of seizures, and epilepsy syndrome, electroencephalography and imaging results, and selected AEDs were collected. Seizure types, etiology and epilepsy syndromes were classified according to the International League Against Epilepsy Proposal for Revised Classification of Epilepsies and Epileptic Syndromes. 22 The patients diagnosed with epilepsy that do not fit any defined syndromes, patients with generalized epilepsy with febrile seizures plus and patients with frontal lob epilepsy were also included into the study if the patients had no known or presumptive underlying metabolic or structural cause of epilepsy.
Patients were considered to be seizure-free if they had no more seizures for at least 12 months on a stable dose in monotherapy or breakthrough seizures only with missed doses of medication. A first-drug treatment failure was defined discontinuation of the AED due to lack of seizure control despite being able to tolerate the medication in maximum doses (lack of efficacy), or intolerable adverse events. At our hospital, if the medication controls seizures to a reasonable degree, but not entirely at the maximal therapeutic dose without causing adverse effects, normally an adjunct AED is added to the first drug, instead of changing the drug altogether; and if seizures stop for a reasonable period, the first antiepileptic drug then tapered. In these cases, also, the first drug was considered as a treatment failure in the present study.
Tolerability and adverse events were assessed by documenting adverse events spontaneously reported by the parents or the children. Adverse events were classified as major and minor events according to their severity. Major adverse events were defined as events leading to cessation of AEDs. Weight gain was considered major adverse event when the patients gained more than 10% of their pre-treatment weight or when it caused intolerable anxiety. Adverse events which were tolerated by modification of the dosing scheme, symptomatic or supportive management, or behavioral modification were considered minor adverse events. Adverse psychiatric events including irritability, hyperactivity, agitation, and aggressive behavior were grouped as behavioral or personality changes. Adherence was assessed by direct questioning, physical examination and by measurement of serum drug concentrations for phenobarbital, valproate and carbamazepine.
Children were monitored at the first month after the beginning of drug therapy and at every three months subsequently. At each visit, seizure response, adverse events, medication dose and duration of use, the reason for medication discontinuation, adherence, and random serum levels were recorded. The overall percentage of patients who failed initial treatment, and the reason for each treatment failure were determined. Then, the percentage of failed treatments was analyzed in terms of the AED used, the patient's age, and seizure types to examine how these factors influence first-line treatment options.
Statistics
The data were analyzed using SPSS for Windows software package, version 20.0 (SPSS, Chicago, IL). Continuous variables were expressed as means AE standard deviations. Pearson's chi-square test or Fisher's exact test was used, as appropriate, for analysis of betweengroup differences in discrete variables, and analysis of variance (ANOVA) with a Bonferroni post hoc test was used for continuous variables. Significance was set at the p < 0.05 level in analysis.
Results

Patients
A total of 572 children diagnosed with newly onset epilepsy were identified. Of them, those with symptomatic or cryptogenic epilepsy (n = 119), those with less than 12 month-period of followup (n = 112), patients who developed drug resistant epilepsy after the first drug failure (n = 25), and patients who were lost to followup (n = 27) were excluded from the study. The data of 289 children with newly diagnosed idiopathic epilepsy who received AED monotherapy for at least 12-month period were analyzed. Demographic characteristics of subjects are presented in Table 1 . Of 289 children, 33 (11.4%) received phenobarbital, 142 (49.1%) received valproate, 42 (14.5%) received carbamazepine, 38 (13.1%) received oxcarbazepine, and 34 (11.8%) received levetiracetam monotherapy. All patients treated with phenobarbital, valproate, and carbamazepine had drug concentrations at the therapeutic level.
The mean age was 6.9 AE 4.3 years, ranging from 2 months to 16 years. The mean age was similar within the groups, except for phenobarbital group that consisted of patients younger than the others (p < 0.001). Gender distribution was as follows: 141 (48.8%) female and 148 (51.2%) male, with no significant difference between the treatment groups (p > 0.05).
Overall, 127 (43.9%) had generalized seizures including 77 (26.6%) generalized tonic-clonic seizures, 18 (6.2%) atonic seizures, 13 (4.5%) absence seizures, 12 (4.2%) tonic seizures, 5 (1.7%) myoclonic seizures, and 2 (0.7%) clonic seizures; and 159 (55.0%) had partial seizures. When classified in regard to electroclinical syndromes, 55 (19.0%) patients had benign epilepsy with centrotemporal spikes, 7 (2.4%) childhood epilepsy with occipital paroxysms, 3 (1.0%) frontal lobe epilepsy,7 (2.4) generalized epilepsy with febrile seizures plus, 34 (11.8%) benign infantile epilepsy, 6 (2.1%) benign familial infantile epilepsy, 13 (4.5%) childhood absence epilepsy, and 5 (1.7%) juvenile myoclonic epilepsy. In 159 (55.0%) patients, no specific electroclinical syndrome could be diagnosed. The seizure types and epileptic syndromes were not equally distributed between drug groups. Partial epilepsy was significantly more prevalent among patients received carbamazepine, oxcarbazepine and levetiracetam compared to those treated with phenobarbital and valproate (p < 0.001). Phenobarbital was primarily preferred for benign infantile seizures, whilst the majority of patients with rolandic, occipital or frontal epilepsy were treated with carbamazepine, oxcarbazepine or levetiracetam monotherapy. Patients with absence or juvenile myoclonic epilepsy were treated with valproate. Electroencephalographical abnormality were reported in 209 (72.3%) patients; 29 (13.8%) with generalized and 180 (86.1%) with focal epileptic activity. In the whole group, 35 (16.6%) patients had cerebral MRI abnormalities, which were all considered not relevant to epilepsy.
Treatment failures
Overall, 245 (84.8%) patients became seizure-free with the first prescribed AED at the end of 12 months of therapy (Table 2) . Seizure-free rate was 97% in phenobarbital group, 84.5% in valproate group, 83.3% in carbamazepine group, 73.7% in oxcarbazepine group, and 88.2% in levetiracetam group. There was no significant difference in the proportion of patients with lack of seizure control between the drug groups, suggesting similar efficacy (p = 0.099). The reason of treatment failure in patients receiving valproate was lack of seizure control in 14 (63.6%) patients and major adverse events in 8 (36.4%) patients. Treatment failure was due to lack of seizure control in 9 (90.0%) patients and major adverse events in 1 (10%) patient treated with oxcarbazepine. Two patients (50%) had lack of seizure control and another 2 (50%) had adverse events that resulted in treatment failure in the levetiracetam group. The reason of treatment failure was adverse events in 4 (57.1%) patients and lack of seizure control in 3 (42.9%) patients treated with carbamazepine. In patients treated with phenobarbital, treatment failure was observed in only one (3%) patient who had lack of seizure control. When compared to seizure-free group, treatment failure group had no significant differences in terms of gender, age, seizure type, epileptic syndromes and AEDs used ( Table 3) . The second AEDs chosen in patients with uncontrolled seizures were valproate in 10 (34.5%), levetiracetam in 9 (31.0%), carbamazepine in 8 (27.6%) patients, and oxcarbazapine and lamotrigine in 1 (3.4) patient each. In 19 patients, seizures recurred during taper of the first drug, and they were controlled with dual therapy. In the remaining 10 patients, the first drug tapered without seizure recurrence.
Adverse events
Overall, 80 (27.7%) patients had adverse events (Table 4) . The most frequently reported adverse events were behavioral problems in 36 (12.5%) patients, nausea and/or vomiting in 14 (4.8%) patients, weight gain in 7 (2.4%) patients, and learning difficulties in 6 (2.1%) patients. Rash, hair loss, persistent thrombocytopenia (platelet count < 100,000/mm 3 ), elevated aspartate aminotransferase/alanine aminotransferase levels (at least 3 times above the upper limit of normal), decreased attention, headache, diplopia, hirsutism, fatigue, and tremor were infrequent adverse events encountered. The rate of adverse events between the drug groups was not significantly different (p = 0.729).
Major adverse events that resulted in cessation of antiepileptic medication were reported in 15 (5.2%) subjects. Eight (5.6%) patients treated with valproate had major adverse events that include behavioral problems (2 patients), thrombocytopenia (2 patients), weight gain (1 patient), increased liver function tests (1 patient), nausea and vomiting (1 patient), and tremor (1 patient). Four (9.5%) patients treated with carbamazepine discontinued therapy because of learning difficulties (2 patients) and rash (2 patients). One (2.6%) patient treated with oxcarbazepine had diplopia that led to cessation of treatment. Levetiracetam was discontinued in two (5.9%) patients due to behavioral problems. No patient left the treatment in the phenobarbital group because of adverse events. Of the patients with major adverse events necessitating cessation of the first AED, 12 were switched to levetiracetam and 3 were switched to lamotrigine. All of them were seizure free until cessation of the first AED therapy, however seizures recurred in 1 patient who was switched to levetiracetam therapy. This patient remained seizure-free with topiramate add-on therapy.
In total, 65 (22.5%) patients reported minor adverse events which were managed by modification of the dosing scheme, symptomatic or supportive approach and behavioral modification. The rate of minor adverse events between the drug groups was not significantly different (p = 0.515). Behavioral problems such as irritability or aggressiveness were the most common minor adverse events, observed in 27.3% of patients receiving phenobarbital, 20.6% of patients receiving levetiracetam, 9.5% of patients receiving carbamazepine, 7.0% of patients receiving valproate, and 5.2% of patients receiving oxcarbazepine.
Discussion
Limited data are available on the drug treatment failure rates and effectiveness of the first antiepileptic drug in the context of everyday clinical practice setting in children. The present study has demonstrated that both old AEDs including phenobarbital, valproate and carbamazepine, and new AEDs including oxcarbazepine and levetiracetam were equally effective and similarly well tolerated for the treatment of newly onset idiopathic epilepsy in children.
Efficacy
The rate of seizure control with the first AEDs is higher in children than in adults. While 72.7% of adults with newly or recently diagnosed focal onset epilepsy were found to be seizure-free with valproate monotherapy, this rate was significantly higher at 83.7% in children. 23 In our cohort, overall remission rate for twelve months was 84.8%, which was similar 23 or slightly higher compared to several studies that reported rates of seizure control between 50% and 84% in children treated with first-line AEDs. 3, 8, [11] [12] [13] [14] [15] This higher rate was likely due to study design that included only non-refractory idiopathic epilepsies. A previous study has shown that while 43.5% of adult patients with symptomatic or cryptogenic epilepsy became seizure-free with the first antiepileptic drug, this rate was 58% in patients with idiopathic epilepsy. 8 Another study has demonstrated that children with idiopathic epilepsies had higher rates of effectiveness compared to patients with symptomatic or cryptogenic epilepsies, supporting that our high rates of effectiveness might be associated with the study design enrolling only patients with idiopathic epilepsies. Similar to our rate of effectiveness, a previous study that included only children with generalized tonic clonic, partial and partial with secondary generalized seizures, reported a 80% efficacy rate over the first year.
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A previous study has shown that variables predictive of the drug treatment failure in childhood epilepsy were etiology, seizure type and age at onset. 24 In that study, an onset of epilepsy below one year was associated with higher treatment failure. 24 However, we found no difference between seizure-free and treatment failure groups in regard to age of onset. This may also be due to our study design that excluded patients with refractory epilepsies which are encountered more commonly among epilepsies starting during the first year of life.
Comparisons of efficacy between antiepileptic drugs
In the present study, all AEDs including phenobarbital, valproate, carbamazepine, oxcarbazepine, and levetiracetam had similar efficacy rates. Similarly, a comparative, randomized study comparing the effectiveness of valproate, carbamazepine, phenobarbital and phenytoin under standard conditions of care reported that all treatments were equivalent in terms of efficacy and adverse events. The authors have reported that 73% of patients Table 4 Adverse events of the first antiepileptic drug monotherapy in children with newly onset idiopathic epilepsy. AEDs, antiepileptic drugs.
achieved 1-year remission by 3 years of follow-up, without any significant difference between the treatment groups in terms of effectiveness and tolerability. 3 A recent study investigating the effectiveness of valproate, carbamazepine and oxcarbazepine in children with idiopathic and symptomatic epilepsies also reported similar effectiveness and failure rates between the treatment groups.
14 Limited data are available on effectiveness of new AEDs such as oxcarbazepine and levetiracetam. In the present study, both old and new AEDs had similar effectiveness. In a previous study, levetiracetam monotherapy resulted in more than 50% reduction in seizures in 90% of patients taking the treatment, 19 which was comparable with our seizure control rate of 88.1%. In contrast, a recent study has shown that initial monotherapy of levetiracetam failed more frequently due to a lack of effectiveness than a monotherapy with valproate or oxcarbazepine. 17 In another study, oxcarbazepine led to more than 50% reduction in seizures in 90% of children when used as first-line treatment in children, of those 44% achieved seizure freedom. 18 In consistent with this report, 73.7% of patients were seizure-free for 12 months in our study.
Adverse events
Adverse effects are one of the leading causes of treatment failure in epileptic patients. They result in early treatment discontinuation in up to 25% of patients, and also preclude attainment of fully effective doses and have a negative effect on patient adherence. 25, 26 The old AEDs has complex pharmacokinetics. Among them, phenytoin, carbamazepine, phenobarbital and primidone are hepatic enzyme inducers. 27 Enzyme-inducing AEDs produce important interactions with many commonly used medications, such as warfarin, oral contraceptives, calcium channel antagonists, and chemotherapeutic agents. Many of the new agents have little, if any, effect on the CYP450 enzyme system and other metabolic pathways. However, drug interactions were also assessed in the present study. Overall 27.7% of patients reported adverse events, of those the most common ones were behavioral or personality changes, nausea and/or vomiting, weight gain, and learning difficulties. In a previous study, behavioral or personality changes were noted in about 15-20% of patients with epilepsy who were treated with antiepileptic drugs. 28 Similarly, 12.5% of patients in our study had behavioral or personality changes.
Children can be more vulnerable to adverse effects than adults, and the toxic effect profile of AEDs may differ from that of adults. In particular, behavioral changes such as hyperactivity, irritability, insomnia, and aggression induced by barbiturates occur more frequently in children than in adults. 29, 30 Similarly, we observed behavioral changes such as irritability in 8 (24.2%) patients and fatigue in 2 (6.1%) patients receiving phenobarbital. Barbiturates are also known to have the most detrimental effects on cognition. 29 In our study, no systematic evaluation was done to search for the effects of phenobarbital on cognitive functions in relatively shortterm follow-up period; however, we may speculate that behavioral changes such as irritability and fatigue were likely to be the initial indicators of cognitive impairment. Obviously, this issue needs to be clarified with prospective studies.
Valproate was another drug that was commonly associated with behavioral problems in our study. Of patients receiving valproate, 26.1% had adverse events, of those the most common ones were behavioral problems followed by weight gain, nausea/ vomiting, hair loss and learning difficulties. Behavioral changes along with persisted thrombocytopenia were the most common adverse events leading to cessation of valproate treatment. In a previous study, 10% of children receiving valproate showed adverse events, of them weight gain and alopecia were mostly reported. 23 Weight gain is commonly associated with valproate and to a lesser extent with carbamazepine. 31 We observed weight gain in 6 patients receiving valproate and in one patient taking oxcarbazepine, however only one patient in the valproate group discontinued treatment because of weight gain. Antiepileptic druginduced hepatotoxic effects can occur in epileptic patients. 32 Risk of fatal hepatic failure is estimated at one in 500 for high-risk pediatric patients (age <2 years, inborn metabolic disorders, and polytherapy) receiving valproate. 33 In our series, only one patient in the valproate group had increased hepatic enzymes levels more than three-fold of the upper limit of normal range. Since hepatic enzymes did not return to normal values following dose reduction, the patient was switched from valproate to levetiracetam therapy and hepatic enzymes returned to normal values subsequently. Maculopapular rash has been noted in 5-17% of patients treated with carbamazepine and phenobarbital. 34 Similar to previous reports, 8, 13, 14 maculopapuler rash was the most common adverse effect necessitating cessation of carbamazepine treatment in our study. Three (7.1%) of 42 patients receiving carbamazepine developed rashes, which disappeared upon withdrawal of medication in two, and upon reducing the dose in the other patient. No patient reported rash in other treatment groups.
The majority of adverse events seen in patients treated with oxcarbazepine were minor, including nausea and vomiting, behavioral changes and increased appetite. The only patient who discontinued oxcarbazepine treatment due to adverse effects had diplopia, which disappeared after withdrawal of medication. Similarly, in a previous study investigating the effectiveness of oxcarbazepine monotherapy in children, 16.6% of patients reported adverse events including drowsiness, aggressive behavior, ataxia, dizziness, diplopia, and leg cramps. 18 Levetiracetam is a relatively new AED developed primarily for use as an add-on therapy in patients with intractable epilepsy. Thus, limited data are available on its efficacy and tolerability in children as monotherapy. 17, 19 Behavioral adverse effects such as depression, anxiety, and agitation have been reported in 26.9% of patients who used levetiracetam as add-on treatment. 35 In a previous study, aggressiveness was reported in 5% and tiredness in 7% of patients treated with levetiracetam. 19 However, these adverse events were seen only in the add-on group and it was related to the levetiracetam dosage. In our series, four of 34 patients receiving levetiracetam developed behavioral problems, which resulted in discontinuation of treatment in two of them.
Although a previous study has demonstrated that valproate was better tolerated than carbamazepine, 8 in our series there was no significant difference between the drug groups in terms of tolerability. No death or life threatening adverse event was reported during the study period. Our data indicate that adverse events are frequent but not severe in children treated with AEDs, however they are one of the main reasons for withdrawal of AEDs.
Reasons for treatment failure
Overall, 15% of the patients who received first-line AED treatment failed, and adverse events were the reason in one third of them. Several studies have shown that adverse effects and lack of efficacy contributed equally to first-line AED treatment failures in newly diagnosed epilepsy in children. 8, 13, 17 In our study, although slightly less number of cases discontinued the treatment because of adverse events in the oxcarbazepine group, the difference was not significant. In agreement with previous studies, 8, 13, 14 the proportion of treatment failure due to adverse effects or lack of efficacy was similar between the treatment groups.
Limitations of the study
In the present study, AEDs were selected by the doctors on the basis of their experience. Thus, there might be bias in the selection of AEDs for individual patients. For instance, valproate was the only drug prescribed for patients with absence seizures or juvenile myoclonic seizures, while carbamazepine, oxcarbazepine and levetiracetam were prescribed primarily for patients with partial epilepsy. As a retrospective study, we were constrained by the information available on the medical records. However, a standard protocol in our hospital includes baseline blood tests, brain MRI, and EEG studies in all patients diagnosed with newly onset epilepsy before the beginning of AED therapy, and follow up visits at the first month and at every 3 months for the first year and at every 6 months thereafter. The clinician records the results of tests, neurologic examination findings and adverse events reported by the patients or parents on a standardized digital file at every visit. This standardized approach provides a prospective data although the present study is retrospective. The small sample size of phenobarbital, carbamazepine, oxcarbazepine and levetiracetam groups was the other limitation of the study. Levetiracetam and oxcarbazepine are recently began to be used in the initial treatment of childhood epilepsy. Phenobarbital is generally used only for children younger than 2 years of age. On the other hand, valproate is used widely in patients older than two years of age with both generalized and partial epilepsy. This significant difference in the number of patients between drug groups, likely obscured our ability to show some differences between groups. For example, patients received phenobarbital showed greater minor adverse events, however this rate could not reach statistically significance. The cohort specifically excluded children with drug resistant epilepsy in order to provide more homogeneous population in drug groups. However this resulted in the lack of data on efficacy in this population. Lack of assessment of phenytoin and ethosuximide, two older AEDs, is the other limitation of this study. We use rarely these AEDs as a first choice in patients with newly diagnosed epilepsy due to the side effects and low therapeutic index of phenytoin, and due to the unavailability of ethosuximide in our country. Many other new AEDs including gabapentin, lamotrigine, topiramate, tiagabine,-vigabatrine, felbamate, and zonisamide were not assessed in this study, because they were not approved as first line therapy in patients with new onset idiopathic epilepsy, and also because of their high cost. Since we do not screen routinely in our daily clinical practice, the metabolic complications of AEDs such as osteomalacia, hyperlipidemia or hyponatremia were not assessed in this study. The frequency of adverse events was determined with spontaneous reporting, which likely underestimated the burden of AED toxic effects. On contrary, use of screening measures, such as questionnaires or checklists, might likely have resulted in overestimation, as suggested previously. 36 Indeed, in a previous study, adverse effects of AEDs were reported in 34% of patients when assessed by means of spontaneous reporting and in 65% when a checklist was used. 37 
Conclusion
In conclusion, the majority of patients with newly diagnosed idiopathic epilepsy become seizure-free with the first prescribed AED in daily clinical practice. In addition to seizure control, the overall effectiveness is also determined by adverse events, which are responsible for approximately one third of treatment failures. It appears that old (phenobarbital, valproate and carbamazepine) and new AEDs (oxcarbazepine and levetiracetam) have similar efficacy and tolerability profiles.
